Form 4: Sage Therapeutics Director Disposes of All Holdings Following Merger Completion

Sage Therapeutics director James M. Frates reported the disposal of all his common stock and stock options as the company's merger with Supernus Pharmaceuticals became effective on July 31, 2025.

Summary

• Reporting person James M. Frates, a director of Sage Therapeutics, Inc., reported the disposal of all his beneficial ownership in Sage Therapeutics common stock and stock options.
• The transactions occurred on July 31, 2025, which was the effective date of the merger between Sage Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
• Frates disposed of 2,845 shares of common stock.
• He also disposed of 19,154 stock options with an exercise price of $6.14 and 21,500 stock options with an exercise price of $6.77.
• Following these transactions, Frates holds 0 shares of common stock and 0 derivative securities in Sage Therapeutics.
• Under the merger terms, each issued and outstanding common share was cancelled and converted into the right to receive $8.50 in cash (the 'Closing Amount') plus one Contingent Value Right (CVR).
• Each CVR represents the right to receive up to an additional $3.50 in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer on June 16, 2025.
• Stock options with a per share exercise price less than the $8.50 Closing Amount were deemed fully vested, cancelled, and converted into a cash payment equal to the product of the excess of the Closing Amount over the exercise price, multiplied by the total number of shares subject to the option, plus one CVR for each share subject to such option.
• Stock options with a per share exercise price greater than or equal to the $8.50 Closing Amount were cancelled with no consideration payable.

Sentiment

Score: 7

Explanation: The filing is a factual report of a director's share and option disposal due to a completed merger. The merger terms provide a fixed cash component and a contingent value right, which is a standard outcome for such corporate actions. The sentiment is neutral as it reports a completed event rather than new operational news, but the merger itself is generally a positive liquidity event for shareholders.

Positives

• Merger completion provides former shareholders with immediate cash value of $8.50 per share.
• Contingent Value Rights (CVRs) offer potential for additional cash payments of up to $3.50 per share based on future milestone achievements.
• Stock options with exercise prices below the merger consideration were cashed out, providing value to option holders.

Negatives

• Former Sage Therapeutics shareholders no longer hold equity in the company, as their ownership has been converted into cash and CVRs.
• Stock options with exercise prices equal to or greater than the $8.50 Closing Amount were cancelled without consideration.

Risks

• The realization of the full value of the Contingent Value Rights (CVRs) is dependent on the satisfaction of specified milestones, meaning the additional $3.50 per share may not be fully achieved.

Future Outlook

The future outlook for former Sage Therapeutics shareholders is tied to the performance of Supernus Pharmaceuticals and the achievement of milestones associated with the Contingent Value Rights, which could yield up to an additional $3.50 per share.

Industry Context

This merger represents a consolidation within the biotechnology and pharmaceutical sectors, where larger companies often acquire smaller, specialized firms to expand their pipeline or market share. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech acquisitions to bridge valuation gaps and share future development risks/rewards, particularly for assets in clinical development.

Comparison to Industry Standards

• The merger consideration of $8.50 cash plus a CVR up to $3.50 per share is a specific deal structure. Without knowing Sage Therapeutics' pre-merger valuation, pipeline, and market conditions, a direct comparison to industry benchmarks like recent biotech acquisitions (e.g., Pfizer's acquisition of Seagen, AbbVie's acquisition of ImmunoGen) is difficult.
• However, CVRs are a standard tool in biotech M&A, often used when there is significant future value tied to clinical or regulatory milestones, similar to how they were structured in deals like Bristol Myers Squibb's acquisition of Celgene or Sanofi's acquisition of Synthorx.

Stakeholder Impact

• Shareholders: Former Sage Therapeutics shareholders receive cash and CVRs, converting their equity ownership.
• Employees: While not explicitly stated, mergers often lead to organizational restructuring and potential changes for employees.
• Customers/Suppliers: The merger could impact future product development and supply chains, but the filing does not provide details.

Next Steps

• Former Sage Therapeutics shareholders will receive the $8.50 cash consideration per share.
• Former Sage Therapeutics shareholders will receive Contingent Value Rights (CVRs), which may pay out up to an additional $3.50 per share upon the satisfaction of specified milestones.
• Supernus Pharmaceuticals, Inc. will integrate Sage Therapeutics' assets and operations.

Key Dates

Keywords

Sage Therapeutics, Supernus Pharmaceuticals, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Contingent Value Rights, CVR, Biotechnology, Pharmaceuticals, Corporate Action, Shareholder Value